InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026)

InMed Pharmaceuticals has reported Return on Capital Employed for 5 years, with the latest figure at 115.49% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 302.0% year-over-year to 115.49%; the trailing twelve-month figure through Mar 2026 stood at 115.49% (down 302.0% YoY), and the FY2025 full-year result was 66.99%, up 757.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 115.49%, down from 76.87% in the prior quarter.
• The five-year high for Return on Capital Employed was 52.02% in Q1 2024, with the low at 172.51% in Q3 2022.
• Historically, Return on Capital Employed has averaged 94.37% across 5 years, with a median of 78.09% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed soared 10517 bps — and 2025, when it sank 6045 bps.
• InMed Pharmaceuticals' Return on Capital Employed stood at 118.71% in 2022, then soared by 49 bps to 60.98% in 2023, then plunged by 68 bps to 102.27% in 2024, then gained by 25 bps to 76.87% in 2025, then tumbled by 50 bps to 115.49% in 2026.
• The last three Return on Capital Employed figures came in at 115.49% (Q1 2026), 76.87% (Q4 2025), and 65.43% (Q3 2025), per Business Quant data.